{"id":18136,"date":"2025-09-12T00:02:09","date_gmt":"2025-09-11T18:32:09","guid":{"rendered":"http:\/\/43.205.138.160\/?post_type=article&p=18136"},"modified":"2025-09-12T00:02:41","modified_gmt":"2025-09-11T18:32:41","slug":"daily-chart-analysis-on-syngene","status":"publish","type":"article","link":"https:\/\/signalz.pro\/article\/daily-chart-analysis-on-syngene\/","title":{"rendered":"Daily Chart Analysis on SYNGENE"},"content":{"rendered":"

Daily Chart Analysis on SYNGENE on 11092025<\/a>Technical Analysis (Daily Chart)<\/strong><\/p>\n

Trend & Price Action<\/strong>:
\nThe stock is currently trading at \u20b9661<\/strong>, showing recovery from recent lows near \u20b9625. After a corrective phase, buyers are returning around key support zones.<\/p>\n

Moving Averages<\/strong>:
\nPrice has reclaimed 20-DMA & 50-DMA<\/strong>, indicating short-term strength.
\nStock is attempting to cross 100-DMA (~\u20b9665)<\/strong> which acts as immediate resistance.
\n200-DMA near \u20b9705<\/strong> remains a bigger hurdle for medium-term uptrend.<\/p>\n

Indicators<\/strong>:
\nRSI (14) ~52<\/strong>: Neutral, showing recovery momentum but not yet overbought.
\nMACD<\/strong>: Bearish crossover still intact, though histogram shows narrowing, hinting at a possible reversal.
\nParabolic SAR<\/strong>: Recent candles show buy signal formation as dots shift below price.<\/p>\n

Support & Resistance Levels<\/strong>:
\nSupport<\/strong>: \u20b9640, followed by \u20b9625.
\nResistance<\/strong>: \u20b9665 (immediate), then \u20b9690\u2013705 (medium-term).<\/p>\n

Technical View<\/strong>:
\nThe stock is showing a short-term pullback. Sustaining above \u20b9665 could open room towards \u20b9690\u2013705 levels<\/strong>. On the downside, \u20b9640 is key support; a break below may weaken momentum.<\/p>\n

Fundamental View
\n<\/strong>Syngene is a leading contract research and manufacturing (CRAMS) company<\/strong>, offering integrated services in drug discovery, development, and manufacturing.
\n<\/strong>Backed by Biocon Group<\/strong>, it serves global pharma, biotech, agrochemical, and animal health companies.<\/p>\n

Strengths<\/strong>: Strong global clientele, long-term contracts, R&D capabilities, focus on biologics and specialty chemicals.<\/p>\n

Risks<\/strong>: Global regulatory scrutiny, forex fluctuations, client dependency, and pricing pressures.<\/p>\n

Micro View (Company-specific)<\/strong>
\nStrong Order Book<\/strong>: Robust long-term partnerships with global innovators ensure visibility.
\nCapacity Expansion<\/strong>: New facilities & biologics capabilities to support growth.
\nEarnings Trend<\/strong>: Revenue growth steady in high single digits; margins improving with scale.
\nShort-term Risk<\/strong>: Delay in client R&D spending due to global macro slowdown.<\/p>\n

Macro View (Sector & Economy)
\n<\/strong>India is emerging as a global hub for contract research & manufacturing<\/strong> due to cost advantages, skilled workforce, and regulatory compliance.
\n<\/strong>Global push towards outsourcing in pharma & biotech remains a long-term growth driver.
\n<\/strong>Macro headwinds like US\/EU recession fears<\/strong> or weaker biotech funding may temporarily impact order flows.<\/p>\n

Upcoming Events & Impact
\nQ2 FY26 Results (October 2025)<\/strong>: Key focus on revenue growth, margin expansion, and order inflows.
\nGlobal Pharma Updates<\/strong>: Any pickup in US\/EU biotech R&D spending will positively impact Syngene.
\nRegulatory Updates<\/strong>: Inspections & approvals at manufacturing facilities may act as catalysts.<\/p>\n

Disclaimer
\n<\/strong>This report is prepared only for educational and informational purposes<\/strong>. It should not be considered as investment advice or a buy\/sell recommendation. Stock market investments are subject to risks. Past performance does not guarantee future returns. Please consult a SEBI-registered investment advisor<\/strong> before making any investment decisions.<\/p>\n

Disclosure
\n<\/strong>The author\/analyst has no personal or family holdings<\/strong> in Syngene International Ltd. Views are based on technical chart studies and publicly available data.<\/p>\n

For More Info:
\n<\/strong>Visit Us- www.investogainerresearch.com<\/a>
\nCalls Us- 9009099805, 9098804206
\nEmail- info@investogainerresearch.com<\/a><\/p>\n","protected":false},"template":"","article-category":[35],"article-tags":[400,130,183,121,133,169,92,128,168,127],"class_list":["post-18136","article","type-article","status-publish","hentry","article-category-learn","article-tags-technicalanalysis","article-tags-expert-analysis","article-tags-investingtips","article-tags-investment-opportunities","article-tags-investment-strategies","article-tags-investmentstrategy","article-tags-sebi-registered-advisors","article-tags-sebi-registered-analysts","article-tags-stockmarkettips","article-tags-successful-investing"],"acf":[],"_links":{"self":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article\/18136","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article"}],"about":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/types\/article"}],"wp:attachment":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/media?parent=18136"}],"wp:term":[{"taxonomy":"article-category","embeddable":true,"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article-category?post=18136"},{"taxonomy":"article-tags","embeddable":true,"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article-tags?post=18136"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}